Therapeutic modulation of ocular surface lubrication
US9138457B2 · kind B2 · utility
14Cited by
15References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 5, 2010 |
| Grant date | Sep 22, 2015 |
| Priority date | — |
| Expiry date | Nov 5, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are ophthalmically acceptable pharmaceutical compositions comprising a PRG4 inducing compound in combination with PRG4 (including a lubricant fragments, homologs, or isoforms thereof), and methods of using the same. The PRG4 inducing compound in the pharmaceutical composition of the present invention upregulates PRG4 expression and localization in the ocular surface for efficient surface boundary lubrication. In some instances, pharmaceutical compositions described herein are utilized for treating ophthalmic conditions, e.g., ocular boundary deficiency and symptoms associated therewith.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.